New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
07:04 EDTALNY
theflyonthewall.com: Alnylam Pharmaceuticals new preclinical ALN-VSP data
Alnylam Pharmaceuticals announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. ALN-VSP is an RNAi therapeutic currently in a Phase I clinical trial for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumors with liver involvement. The new data demonstrated robust anti-tumor activity in orthotopic liver tumor models comprised of both HCC- and colorectal cancer-derived cell lines. ALN-VSP was also shown to act on disseminated tumors outside of the liver. Further, in addition to anti-proliferative effects, studies showed that ALN-VSP exerts a potent anti-angiogenic effect on tumors. :theflyonthewall.com



News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
08:13 EDTALNY
theflyonthewall.com: Alnylam awarded a Notice of Allowance for the Soutschek and Manoharan patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent, which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery. The new patent is based on the ground-breaking research by Alnylam scientists on systemic delivery of RNAi therapeutics as documented in Soutschek et al. :theflyonthewall.com